Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Rituximab 'can delay lymphoma'

  • Comment

Immunotherapy treatment administered early enough can delay the onset of symptoms for people with lymphoma, according to research.

Those who have follicular lymphoma are typically given treatment only once symptoms appear but if the antibody drug rituximab is prescribed at diagnosis, the time the patient spends symptom-free can be extended.

Researchers at University College Hospital in London compared the so-called watch and wait practice with early treatment of rituximab in 463 people with the condition.

Nine in 10 of those who were given the drug immediately, as well as subsequent regular doses, were found to have no symptoms three years later, the scientists said.

Half of the patients in the other group went this long without displaying symptoms, such as enlarged glands, weight loss or tumour growth.

Trial leader Kirit Ardeshna said: “These early trial results are encouraging and increase the options available to lymphoma patients. It is likely this new combination will be adopted as a means of delaying the need for chemotherapy in this group of patients.”

The results were presented at the annual meeting of the American Society for Haematology in Florida.

Kate Law, from the charity Cancer Research UK, which part-funded the research, said: “Chemotherapy can often successfully stop lymphoma from progressing for many years but if the cancer recurs or continues to grow then further chemotherapy may not work as well.

“So being able to delay the need for chemotherapy for as long as possible is an important step forward in managing this generally incurable disease.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.